Decreased exhaled nitric oxide in mild persistent asthma patients treated with a leukotriene receptor antagonist, pranlukast.
Exhaled nitric oxide (NO) level decreases after corticosteroid treatment in asthmatics, but the effect of a leukotriene receptor antagonist, pranlukast, on exhaled NO has not been elucidated. Pranlukast treatment in mild persistent asthmatics for 4 weeks decreased the exhaled NO level, which did not differ from the levels in healthy subjects.